摘要:
The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.
摘要翻译:本发明提供具有下式的化合物:其中AB一起表示以下结构之一:n,R 1,R 2,R 3, R 4,L 1,L 2,Y和Z如本文中的类别和亚类所定义,及其药物组合物,如所述 通常和在本文中的亚类中,哪些化合物可用作蛋白激酶(例如RAF)的抑制剂,因此可用于例如治疗RAF介导的疾病。
摘要:
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
摘要:
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
摘要:
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
摘要:
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
摘要:
The present invention provides compounds having the formula: wherein R1, R2, X1, X2, L1, L2, Y and Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
摘要翻译:本发明提供具有下式的化合物:其中R 1,R 2,X 1,X 2, L 1,L 2,Y和Z如本文中的类别和亚临界所定义,以及其在本文中通常和在本文中描述的药物组合物,该化合物可用作 蛋白激酶抑制剂(例如Aurora),因此可用于治疗Aurora介导的疾病。
摘要:
The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: wherein one of is a double bond, as valency permits; and R2, R4, X1A, X2A, X1B, X2B, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.
摘要:
The invention provides compounds of Formula I and derivatives thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of treatment utilizing such compounds and compositions: wherein: R1 is chosen from optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; L is a linker; R2 is chosen from optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and or single stereoisomers, mixtures of stereoisomers, or the pharmaceutically acceptable salts, amides, or esters thereof.
摘要翻译:本发明提供式I化合物及其衍生物,包含式I化合物的药物组合物和使用这些化合物和组合物的治疗方法:其中:R 1选自任选取代的芳基,任选取代的 芳烷基,任选取代的杂芳基和任选取代的杂芳烷基; L是连接体; R 2选自任选取代的芳基,任选取代的芳烷基,任选取代的杂芳基和任选取代的杂芳烷基; 和/或单一立体异构体,立体异构体的混合物,或其药学上可接受的盐,酰胺或酯。